Oncology Hematology Care (OHC) Company Profile

Background

Oncology Hematology Care (OHC) is an independent, physician-led practice specializing in the treatment of adult cancers and complex blood disorders. Established over 30 years ago, OHC has grown to become one of the nation's largest independent oncology practices, offering comprehensive care through a multidisciplinary team of over 50 specialists. The practice is committed to providing leading-edge, compassionate, and convenient care tailored to meet each patient's medical and personal needs.

Key Strategic Focus

OHC's strategic focus centers on delivering high-quality, patient-centered care by integrating advanced medical treatments with personalized support services. Key objectives include:

Comprehensive Cancer Care: Offering a wide range of services, including medical oncology, radiation oncology, gynecologic oncology, and hematology, to address nearly every form of adult cancer and complex blood disorder.

Clinical Research and Trials: Collaborating with the Sarah Cannon Research Institute (SCRI) to provide patients access to innovative treatments through clinical trials, contributing to the advancement of cancer care.

Patient Support Services: Offering financial counseling, disease education, and emotional support to help patients manage the impact of cancer on their lives.

Financials and Funding

As a privately held entity, OHC does not publicly disclose detailed financial information. However, estimates suggest that the practice's annual revenue is in the range of $50 million to $100 million. In 2016, OHC joined The US Oncology Network, gaining access to resources and support to enhance operational efficiency and advance quality care.

Pipeline Development

OHC's clinical trials program, in collaboration with SCRI, offers patients access to a variety of clinical trials across multiple cancer types, including breast, lung, colorectal, prostate, gynecologic cancers, and blood cancers such as multiple myeloma, leukemia, and lymphoma. This collaboration aims to provide patients with early access to promising new treatments.

Technological Platform and Innovation

OHC distinguishes itself through the following technological platforms and innovations:

CAR T-cell Immunotherapy: Administering groundbreaking CAR T-cell therapy for adults with blood cancers, marking a significant advancement in cancer treatment.

Clinical Trials Program: Recognized by the Conquer Cancer Foundation of the American Society of Clinical Oncology for its commitment to high-quality clinical trial programs, offering patients access to cutting-edge treatments.

Biomarker Testing Initiative: Implementing a quality improvement project to standardize comprehensive biomarker testing in patients with metastatic non-small cell lung cancer, enhancing personalized treatment approaches.

Leadership Team

OHC is led by a team of experienced professionals dedicated to advancing cancer care:

Dr. David Drosick: President of OHC, overseeing the practice's strategic direction and operations.

Dr. Randolph Broun: Medical Oncologist and Practice President, leading clinical initiatives and patient care strategies.

Molly Mendenhall, RN, BSN: Director of Quality and Compliance, recognized for implementing quality improvement projects in cancer care.

Market Insights and Competitive Landscape

The oncology care market is characterized by a growing demand for specialized cancer treatments, advancements in immunotherapy, and an increasing emphasis on personalized medicine. Independent practices like OHC play a crucial role in providing accessible, community-based care, complementing larger hospital systems and academic centers.

OHC operates in a competitive landscape that includes:

Texas Oncology: A network of over 460 physicians providing advanced cancer treatments across Texas, New Mexico, and Oklahoma.

Seattle Cancer Care Alliance: A comprehensive cancer treatment and research center in Seattle, Washington, offering a wide range of oncology services.

Harris Health System: A large healthcare provider with significant revenue, offering a range of medical services, including oncology care.

Strategic Collaborations and Partnerships

OHC's partnership with The US Oncology Network enhances its operational efficiency and access to advanced cancer treatments. Additionally, collaborations with SCRI expand the availability of clinical trials, providing patients with access to innovative therapies.

Operational Insights

OHC's independent, physician-led model allows for personalized, patient-centered care, distinguishing it from larger hospital systems. The practice's commitment to quality, as evidenced by its QOPI certification and recognition by the Conquer Cancer Foundation, underscores its dedication to high standards in oncology care.

Strategic Opportunities and Future Directions

OHC is well-positioned to expand its services by:

Enhancing Clinical Trials: Increasing the number and diversity of clinical trials offered to provide patients with access to cutting-edge treatments.